Therapeutics Startups

Andson Biotech develops analytical tools for the analysis of biotherapeutics, aimed at supporting the discovery and development of biologic drugs.

3 investors

Dorian Therapeutics develops therapeutics aimed at rejuvenating tissue and treating age-related diseases. The company operates in the biotech and anti-aging therapeutics space.

3 investors

Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.

3 investors

Nanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.

3 investors

Exin Therapeutics develops an AI-guided drug discovery platform that uses experimental mouse studies to identify neurological therapies, starting with epilepsies linked to autism and Parkinson's disease. The company trains machine learning models on proprietary multimodal neuroscience data to guide its therapeutic screening process.

2 investors

Intact Therapeutics is developing an advanced materials platform that uses smart gels to deliver and absorb drugs locally within the digestive tract. The company aims to improve treatment for a range of gastrointestinal disorders.

2 investors

Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.

2 investors

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

2 investors

SynsoryBio develops protein-based drugs that detect their location in the body and activate only at diseased tissue, with applications across cancer and autoimmune conditions.

2 investors

Adventris is a biotechnology company developing cancer immunotherapy treatments.

1 investor

Cisterna Biologics develops yeast-engineered mRNA manufacturing technology that can be selectively purified to drive protein expression in human cells. The company targets cost-effective, scalable, and non-immunogenic mRNA production for therapeutic applications.

1 investor

EncepHeal develops small-molecule medications to treat substance use disorders, with a lead therapeutic targeting stimulant addiction such as cocaine and methamphetamine. Its compounds act as atypical/allosteric modulators of the dopamine transporter, developed with partners at the NIH and Wake Forest.

1 investor

Eris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.

1 investor

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

Evolvere BioSciences develops antibiotics using computational models and evolutionary data to target pathogenic bacteria while preserving beneficial microbes, designed to resist the development of bacterial resistance.

1 investor

Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.

1 investor

KemNet provides modified versions of existing pharmaceuticals to pharmacies, tailored for specific patient populations with altered formulations that aim for improved efficacy across indications including sexual dysfunction, hair loss, pain management, weight reduction, and women's health.

1 investor

Macromoltek is a computational drug design company that uses a proprietary platform to produce de novo antibody designs, including against difficult targets not accessible through traditional methods. It serves large biopharmaceutical companies and smaller biotechs.

1 investor

Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.

1 investor

Relevium Medical is a biopharmaceutical company developing long-lasting treatments for chronic pain conditions, particularly osteoarthritis. The company focuses on therapeutic hydrogels and drug discovery for patients with debilitating pain.

1 investor